

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 13/03/2018

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	DATA CTS	AIC	CONFEZIONE
Hizentra	EMEA/H/C/2127/II/74	J06BA01	Immunoglobulina umana normale	CSL Behring GmbH	14-set-17	30-gen-18	23-feb-18	14-mar-18	041157153	15
Hizentra	EMEA/H/C/2127/II/74	J06BA01	Immunoglobulina umana normale	CSL Behring GmbH	14-set-17	30-gen-18	23-feb-18	14-mar-18	041157165	16
Hizentra	EMEA/H/C/2127/II/74	J06BA01	Immunoglobulina umana normale	CSL Behring GmbH	14-set-17	30-gen-18	23-feb-18	14-mar-18	041157177	17
Hizentra	EMEA/H/C/2127/II/74	J06BA01	Immunoglobulina umana normale	CSL Behring GmbH	14-set-17	30-gen-18	23-feb-18	14-mar-18	041157189	18
Nplate	EMEA/H/C/942/II/60/G	B02BX04	romiplostim	Amgen Europe B.V.	09-nov-17	30-gen-18	23-feb-18	14-mar-18	039002098	9
Nplate	EMEA/H/C/942/II/60/G	B02BX04	romiplostim	Amgen Europe B.V.	09-nov-17	30-gen-18	23-feb-18	14-mar-18	039002100	10
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929015	1
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929027	2
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929039	3
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929041	4
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929054	5
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929066	6
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929078	7
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929080	8
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929092	9
Darunavir Krka	EMEA/H/C/4273	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	26-gen-18	23-feb-18	14-mar-18	045929104	10
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930017	1
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930029	2
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930031	3
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930043	4
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930056	5
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930068	6
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930070	7
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930082	8
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930094	9
Darunavir Krka d.d.	EMEA/H/C/4891	J05AE10	darunavir	Krka d. d., Novo Mesto	09-nov-17	18-gen-18	23-feb-18	14-mar-18	045930106	10
Mvasi	EMEA/H/C/4728	L01XC07	bevacizumab	Amgen Europe B.V.	09-nov-17	15-gen-18	23-feb-18	14-mar-18	045925017	1
Mvasi	EMEA/H/C/4728	L01XC07	bevacizumab	Amgen Europe B.V.	09-nov-17	15-gen-18	23-feb-18	14-mar-18	045925029	2
Jorveza	EMEA/H/C/4655	A07EA06	budesonide	Dr Falk Pharma GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045928013	1
Jorveza	EMEA/H/C/4655	A07EA06	budesonide	Dr Falk Pharma GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045928025	2
Jorveza	EMEA/H/C/4655	A07EA06	budesonide	Dr Falk Pharma GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045928037	3
Jorveza	EMEA/H/C/4655	A07EA06	budesonide	Dr Falk Pharma GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045928049	4
Jorveza	EMEA/H/C/4655	A07EA06	budesonide	Dr Falk Pharma GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045928052	5
Cimzia	EMEA/H/C/1037/II/57/G	L04AB05	certolizumab pegol	UCB Pharma S.A.	21-apr-17	08-gen-18	23-feb-18	14-mar-18	039539085	8
Cimzia	EMEA/H/C/1037/II/57/G	L04AB05	certolizumab pegol	UCB Pharma S.A.	21-apr-17	08-gen-18	23-feb-18	14-mar-18	039539097	9
Cimzia	EMEA/H/C/1037/II/57/G	L04AB05	certolizumab pegol	UCB Pharma S.A.	21-apr-17	08-gen-18	23-feb-18	14-mar-18	039539109	10
Orkambi	EMEA/H/C/3954/X/20	R07AX30	Lumacaftor / ivacaftor	Vertex Pharmaceuticals (Europe) Limited	09-nov-17	08-gen-18	23-feb-18	14-mar-18	044560047	5
PREVYMIS	EMEA/H/C/4536	J05AX18	letermovir	Merck Sharp & Dohme Limited	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045890011	1
PREVYMIS	EMEA/H/C/4536	J05AX18	letermovir	Merck Sharp & Dohme Limited	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045890023	2
PREVYMIS	EMEA/H/C/4536	J05AX18	letermovir	Merck Sharp & Dohme Limited	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045890035	3
PREVYMIS	EMEA/H/C/4536	J05AX18	letermovir	Merck Sharp & Dohme Limited	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045890047	4
Fasenra	EMEA/H/C/4433	pending	benralizumab	AstraZeneca AB	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045931019	1
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936010	1
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936022	2
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936034	3
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936046	4
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936059	5
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936061	6
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936073	7

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 13/03/2018

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	DATA CTS	AIC	CONFEZIONE
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936085	8
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936097	9
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936109	10
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936111	11
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936123	12
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936135	13
ADYNOVI	EMEA/H/C/4195	B02BD02	rurioctocog alfa pegol	Baxalta Innovations GmbH	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045936147	14
Ocrevus	EMEA/H/C/4043	L04AA36	ocrelizumab	Roche Registration Limited	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045889019	1
Ocrevus	EMEA/H/C/4043	L04AA36	ocrelizumab	Roche Registration Limited	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045889021	2
Fulvestrant Mylan	EMEA/H/C/4649	L02BA03	fulvestrant	Mylan S.A.S.	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045924014	1
Fulvestrant Mylan	EMEA/H/C/4649	L02BA03	fulvestrant	Mylan S.A.S.	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045924026	2
Intrarosa	EMEA/H/C/4138	pending	prasterone	Endoceutics Ltd.	09-nov-17	08-gen-18	23-feb-18	14-mar-18	045933013	1
Granpidam	EMEA/H/C/4289/IAin/1/G	G04BE03	Sildenafil	Accord Healthcare Limited	17-gen-17	30-gen-18	23-feb-18	14-mar-18	045184037	3
Granpidam	EMEA/H/C/4289/IAin/1/G	G04BE03	Sildenafil	Accord Healthcare Limited	17-gen-17	30-gen-18	23-feb-18	14-mar-18	045184049	4
Granpidam	EMEA/H/C/4289/IAin/1/G	G04BE03	Sildenafil	Accord Healthcare Limited	17-gen-17	30-gen-18	23-feb-18	14-mar-18	045184052	5

La responsabilità di qualsiasi onere e/o attività che l' Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all' immissione in commercio del medicinale, è totalmente a carico dell' Azienda stessa. L' ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.